Ivermectin and Mebendazole Combined with Immune Checkpoint Inhibitors, Vitamin D3, and High-Bioavailable Curcumin in Metastatic Prostate Cancer: A Modeling Study

By Editorial Team

Abstract

Background: Metastatic prostate cancer remains incurable, with limited response to immune checkpoint inhibitors (ICIs) as monotherapy. Preclinical evidence suggests repurposed antiparasitic agents such as ivermectin and mebendazole may have anti-cancer effects, particularly when combined with nutraceuticals like curcumin and vitamin D3.

Objective: This study simulated the efficacy and safety of combining high-dose ivermectin and mebendazole with ICIs, high-bioavailable curcumin, and vitamin D3 in a virtual cohort of metastatic prostate cancer patients.

Methods: A cohort of 4,000 virtual patients (1,000 per treatment arm) was simulated. Four treatment arms were modeled: (1) ICI monotherapy (control), (2) ICI + ivermectin + mebendazole, (3) ICI + ivermectin + mebendazole + curcumin, and (4) ICI + ivermectin + mebendazole + curcumin + vitamin D3. Outcomes included objective response rate (ORR), mean overall survival (OS), progression-free survival (PFS), and serious adverse event (SAE) rates. Subgroup analysis was conducted for biomarker-positive patients (40% of cohort).

Results: ORR increased across treatment arms from 15% (control) to 27% (full combination). Mean OS improved from 18 months to 28.8 months. Mean PFS increased from 6 months to 10.1 months in the full combination arm. SAE rates decreased from 30% to 23% with curcumin and vitamin D3. Biomarker-positive patients demonstrated a 10–15% higher response rate and longer PFS than biomarker-negative patients.

Conclusions: Simulated modeling suggests that combining repurposed antiparasitic and nutraceutical agents with ICIs may significantly enhance treatment outcomes in metastatic prostate cancer, particularly in biomarker-positive individuals. Prospective clinical trials are warranted.

Keywords: Prostate Cancer, Ivermectin, Mebendazole, Immune Checkpoint Inhibitors, Curcumin, Vitamin D3, Repurposed Drugs, Simulation, Modeling Study

Introduction

Despite advances in prostate cancer treatment, metastatic castration-resistant prostate cancer (mCRPC) remains a clinical challenge. Immune checkpoint inhibitors (ICIs) have shown limited efficacy as monotherapy in unselected prostate cancer populations due to a generally immunosuppressive tumor microenvironment.

Emerging evidence suggests potential anticancer activity of repurposed drugs such as ivermectin and mebendazole. These agents exhibit cytotoxicity, inhibit cancer stem cells, and modulate immune response. Likewise, nutraceuticals including high-bioavailable curcumin and vitamin D3 have demonstrated anti-inflammatory and immunomodulatory properties.

This study models the theoretical benefit of integrating these compounds with ICIs to improve outcomes in metastatic prostate cancer using a virtual cohort simulation.

Methods

Cohort Simulation

A total of 4,000 virtual patients were generated and evenly randomized into four arms:

  1. ICI Only (Control)

  2. ICI + Ivermectin + Mebendazole

  3. ICI + Ivermectin + Mebendazole + Curcumin

  4. ICI + Ivermectin + Mebendazole + Curcumin + Vitamin D3

Demographics were standardized across arms. All simulations assumed moderate ICI responsiveness and treatment for advanced disease.

Outcome Measures

  • ORR: Simulated as binomial outcomes based on estimated drug synergy (range: 15–27%).

  • PFS and OS: Modeled as normal distributions, modified by treatment arm.

  • SAEs: Estimated by binomial distribution, reduced in arms containing curcumin and vitamin D3.

  • Biomarker Status: 40% of patients were assigned biomarker-positive status (e.g., mismatch repair deficiency, PD-L1 expression), which influenced treatment response.

Assumptions

  • Additive or synergistic effects between ivermectin, mebendazole, curcumin, and vitamin D3.

  • Safety signals based on published tolerability data in repurposing literature.

Results

Overall Treatment Outcomes

Biomarker-Stratified Outcomes

Subgroup analysis based on simulated biomarker status revealed differential efficacy across treatment arms. Patients with MSI-H tumors—representing approximately 5% of the cohort—demonstrated the greatest relative benefit from the addition of repurposed agents. In the full combination arm (ICI + ivermectin + mebendazole + curcumin + vitamin D3), the objective response rate (ORR) in MSI-H patients exceeded 50%, with median progression-free survival (PFS) extending beyond 12 months and overall survival (OS) surpassing 32 months on average.

Similarly, patients with TMB-high (10%) or CDK12 biallelic loss (7%) tumors showed substantial improvements in ORR (35–45%) and PFS (9–11 months) in response to combination therapy, especially in arms including curcumin and vitamin D3. PD-L1–high patients (25% of the cohort) exhibited more modest but still significant gains, particularly in triple and quadruple agent arms, with ORR rising from 20% in the ICI-only group to 30–37% in the full combination group.

Conversely, biomarker-negative patients—comprising 53% of the population—had lower absolute response rates across all arms, though still experiencing stepwise benefit with each added agent. Their ORR ranged from 12% (ICI-only) to 22% (full combination), with PFS gains averaging 2–3 months and OS improvements of 6–8 months compared to control. These findings support the hypothesis that biomarker stratification, particularly by MSI status, TMB, and immune gene alterations (e.g., CDK12 loss), may identify patients most likely to benefit from rational repurposed drug combinations in metastatic prostate cancer.

Discussion

This modeling study demonstrates that strategic combinations of repurposed agents and nutraceuticals may improve clinical outcomes in metastatic prostate cancer. Notably, ivermectin and mebendazole appear to enhance tumoricidal effects, while curcumin and vitamin D3 contribute to immune modulation and reduced toxicity.

The simulation also highlights the importance of biomarker stratification, with biomarker-positive patients deriving greater benefit—consistent with clinical trends seen in ICI-based therapies.

Limitations include reliance on preclinical assumptions, lack of pharmacokinetic modeling, and need for validation in animal and human models.

Conclusion

The combination of high-dose ivermectin, mebendazole, curcumin, vitamin D3, and ICIs may enhance efficacy and reduce toxicity in metastatic prostate cancer, particularly in biomarker-positive cases. These findings support the rationale for future in vivo validation and exploratory clinical trials.

Notes

  • This study is a computational simulation based on estimated hazard ratios and survival functions, not real patient data.

  • The intervention protocol should not be self-administered without physician supervision.

  • Ethical approval would be required prior to real-world implementation.

Comments

Post a Comment

Popular posts from this blog

Fenbendazole vs Ivermectin for Cancer: Differences and Which Is Better?

By Editorial Team
Image
Cancer patients are increasingly inquiring about the use of the anthelmintic drugs Fenbendazole (FenBen) and Ivermectin (IVM) as potential treatments for cancer. Notably, these patients typically fall into two distinct groups, neither of which represents the usual stage 1 or 2 cancer cases where conventional therapies often show promise. The first group consists of older men whose lung or prostate cancer has recurred. Having undergone conventional treatments previously without success, they express skepticism about its effectiveness this time around. The second, larger group comprises younger patients under 40 dealing with aggressive breast cancer, colorectal cancer, or lymphoma—forms of early-onset cancers that appear to lack the typical mutations observed in traditional cases. This article aims to delve into the differences between Fenbendazole and Ivermectin by examining their me...
Read more

Exploring Ivermectin, Mebendazole and Fenbendazole as Aggressive Cancer Treatments: Research, Protocols, and Controversies (2025)

By Editorial Team
Image
Fenbendazole and ivermectin, both antiparasitic drugs that have shown potential in cancer treatment through several mechanisms, such as slowing cancer cell growth and boosting the immune response. Fenbendazole is being studied for its ability to disrupt energy production in cancer cells, effectively hindering their growth. Ivermectin, on the other hand, has been explored in combination with checkpoint inhibitors to boost the immune system's response to tumors—especially in challenging cases like triple-negative breast cancer. Introduction Cancer remains a leading cause of morbidity and mortality worldwide, with an increasing incidence of aggressive and treatment-resistant tumors such as triple-negative breast cancer (TNBC), pancreatic adenocarcinoma, and glioblastoma. Despite significant advances in targeted therapies and immunotherapies, many patients continue to face limited effective options, highlighting an urgent need for novel, affordable, and accessible treatment strategies....
Read more

Top 10 Cancer Fighting Supplements: Evidence Based Literature Review (2025)

By Editorial Team
Image
Are you overwhelmed by conflicting advice on cancer, diet, and supplements ? You’re not alone. With so many claims out there, it’s hard to separate fact from fiction . Can certain foods lower your cancer risk ? Are some foods increasing it without you realizing? What about vitamin and mineral supplements —do they help prevent cancer, or could they actually increase your risk ? The term " anti-cancer supplements " can be misleading. While some nutrients support the body in cancer prevention or treatment, others may interfere with therapies or even pose risks. This guide compiles over 500 scientific references on cancer, diet, and supplements—helping you navigate the facts with ...
Read more

Ivermectin for Cancer Treatment: Protocols and Evidence (2025 Edition)

By Editorial Team
Image
Ivermectin, a drug primarily used to treat parasitic infections, has gained attention for its potential anti-cancer properties, particularly in alternative treatment protocols. Popularized by figures like Dr. William Makis, these protocols combine ivermectin with supplements and lifestyle changes to target aggressive cancers. This article explores the science, protocols, case reports, risks, and controversies surrounding ivermectin’s use in cancer treatment, providing a balanced guide for readers. What is the Ivermectin Cancer Protocol? Ivermectin cancer protocols, notably those developed by Dr. William Makis, combine ivermectin with supplements like curcumin, vitamin D, and berberine, alongside dietary and lifestyle changes. These protocols are tailored to cancer severity, with higher doses recommended for aggressive cases. The term “turbo cancers,” used by some proponents, refers to rapidly progressing cancers, though it is not a standard medical term and lacks clear scientific defin...
Read more

Fenbendazole and Ivermectin for Cancer Case Series: Over 150 Case Reports (2025)

By Editorial Team
Image
Anecdotal reports and preliminary studies suggest that ivermectin and fenbendazole, both antiparasitic drugs, may have potential anticancer effects when used alongside other treatments.  Many people immediately dismiss the potential of ivermectin and fenbendazole when they learn it is “horse or dog medicine”. That initial reaction is overcome when genuine human success stories are told including the lack of serious side effects. The testimonials you are about to read are from individuals who have bravely shared their experiences in the hope of inspiring and uplifting others. These are raw human accounts, unfiltered by gatekeepers—not peer-reviewed studies—but they offer insights that may be valuable to those searching for options. However, we acknowledge that robust clinical trials are needed to provide more conclusive scientific evidence. Table of Contents: Editor's Preface Introduction Fenbendazole and Ivermectin Case Series Compilation (alphabetical) Breast Cancer Success Storie...
Read more

Fenbendazole and the Joe Tippens Protocol: A Comprehensive Guide (2025)

By Editorial Team
Image
The Joe Tippens Cancer Protocol has gained attention as an alternative approach to cancer treatment, popularized by Joe Tippens, a cancer survivor who credits his recovery to fenbendazole, a veterinary anthelmintic, combined with supplements. This article provides a step-by-step guide to the protocol, explores its scientific basis, shares case reports, and discusses risks and controversies to help readers make informed decisions. What is the Joe Tippens Protocol? The Joe Tippens Protocol involves fenbendazole, a drug typically used to treat parasitic infections in animals, alongside supplements and lifestyle changes. The protocol aims to disrupt cancer cell growth, though it remains experimental and lacks approval for human use by regulatory bodies like the FDA. Below is a summary of the protocol’s components, as updated in 2020: Lifestyle Recommendations : Diet : Eliminate refined sugars and processed foods; focus on whole foods like vegetables, lean proteins, and healthy fats. Exerci...
Read more

Fenbendazole Dosage for Cancer in Humans: Benefits, Risks, and Guidelines (2025)

By Editorial Team
Image
What is Fenbendazole? Fenbendazole is an anthelmintic drug commonly used to treat parasitic infections in animals. However, recent research and anecdotal reports suggest it may have potential anticancer properties in humans. How Does Fenbendazole Work for Cancer? Fenbendazole is believed to work by disrupting microtubules in cancer cells, leading to cell cycle arrest and apoptosis (cell death). Some studies suggest it may also modulate glucose metabolism, limiting cancer cell energy supply. Recommended Fenbendazole Dosage for Cancer in Humans The commonly referenced Joe Tippens Protocol suggests the following dosage: Potential Side Effects of Fenbendazole in Humans While generally considered safe, potential side effects may include: Gastrointestinal discomfort (nausea, diarrhea, bloating) Liver enzyme elevation (rare) Bone marrow suppression (rare) Safety and Precautions Medical Supervision: Always consult with a doctor, especially if combining with other treatments. Drug Interaction...
Read more

Fact Check: Can Ivermectin and Fenbendazole Help Treat Cancer?

By Editorial Team
Image
Ivermectin and fenbendazole, originally developed as antiparasitic drugs, are sparking hope in the fight against cancer, fueled by inspiring stories like those shared by actor  Mel Gibson on The Joe Rogan Experience , where he celebrated friends’ remarkable recoveries. While these medications aren’t yet standard cancer treatments, early research is uncovering exciting potential. Scientists are encouraged by promising lab studies and are calling for more clinical trials to confirm their effectiveness and ensure safe use in humans, paving the way for innovative, accessible therapies that could transform lives. Introduction and Context According to a January 22, 2025 fact-check article by AFP: "The anti-parasitic drugs ivermectin and fenbendazole are not currently recommended for cancer, but posts spread across social media touting the medications after actor  Mel Gibson claimed on the Joe Rogan Experience  that they cured his friends' cases of the disease. Oncology ex...
Read more

How One Cancer Survivor Triggered Interest in Repurposed Anti-Parasitic Drugs

By Editorial Team
Image
Joe Tippens never planned to discover a potential remedy that he credits with saving his life and thrust him into the spotlight among notable cancer survivors. The 67-year-old businessman told The Epoch Times he just wanted to beat a type of cancer with an extremely low survival rate. In August 2016, Tippens was diagnosed with small cell lung cancer with a fist-sized tumor. After undergoing chemotherapy and radiation five times a week in Houston, the large tumor in his left lung was eliminated. However, Tippens said the treatments came closer to killing him than curing him. When he returned home to Oklahoma after the New Year, he received devastating news. His oncologist told him he had zero chance of surviving for more than a few months. “In January of 2017, my PET scan lit up like a Christmas tree and I had wide metastasis everywhere, including in my neck, bones, pancreas, and liver,” Tippens said. Finding a Lifeline Facing a prognosis of three months to live, Tippens heard an intrig...
Read more

2025 Study: Ivermectin and Balstilimab for Stage 4 Triple Negative Breast Cancer - Cedars-Sinai Medical Center Study

By Editorial Team
Image
Authors: Yuan Yuan, Jin Sun Bitar, MaLia Walker, David Lin, January Lee, So Yung Choi, Stephen Shiao, Mourad Tighiouart, Paul H. Frankel, Peter P. Lee Affiliation: Cedars-Sinai Medical Center, Los Angeles, CA Abstract e13146  (2025 ASCO Annual Meeting) is a phase 1/2 study of ivermectin in combination with balstilimab after 1-2 prior lines of therapy for triple negative breast cancer Background: Despite recent FDA approval of immune checkpoint inhibitor (ICI) and antibody-drug conjugates (ADCs), therapeutic options for metastatic triple negative breast cancer (mTNBC) remain limited. Preclinical data showed that ivermectin induces robust T cell infiltration into breast tumors and turning “cold” tumors “hot” in mouse model of TNBC. Balstilimab is a fully humanized IgG4 anti-PD-1 agent with proven safety and efficacy in metastatic cervical cancer. The current phase I/II trial is designed to test the safety and efficacy of the combination of ivermectin and balstilimab in patients wit...
Read more